Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes - PubMed (original) (raw)
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Y Agata et al. Int Immunol. 1996 May.
Abstract
A mAb J43 has been produced against the product of the mouse PD-1 gene, a member of the Ig gene superfamily, which was previously isolated from an apoptosis-induced T cell hybridoma (2B4.11) by using subtractive hybridization. Analyses by flow cytometry and immunoprecipitation using the J43 mAb revealed that the PD-1 gene product is a 50-55 kDa membrane protein expressed on the cell surface of several PD-1 cDNA transfectants and 2B4.11 cells. Since the molecular weight calculated from the amino acid sequence is 29, 310, the PD-1 protein appears to be heavily glycosylated. Normal murine lymphoid tissues such as thymus, spleen, lymph node and bone marrow contained very small numbers of PD-1(+) cells. However, a significant PD-1(+) population appeared in the thymocytes as well as T cells in spleen and lymph nodes by the in vivo anti-CD3 mAb treatment. Furthermore, the PD-1 antigen expression was strongly induced in distinct subsets of thymocytes and spleen T cells by in vitro stimulation with either anti-CD3 mAb or concanavalin A (Con A) which could lead T cells to both activation and cell death. Similarly, PD-1 expression was induced on spleen B cells by in vitro stimulation with anti-IgM antibody. By contrast, PD-1 was not significantly expressed on lymphocytes by treatment with growth factor deprivation, dexamethasone or lipopolysaccharide. These results suggest that the expression of the PD-1 antigen is tightly regulated and induced by signal transduction through the antigen receptor and do not exclude the possibility that the PD-1 antigen may play a role in clonal selection of lymphocytes although PD-1 expression is not required for the common pathway of apoptosis.
Similar articles
- Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.
Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T. Nishimura H, et al. Int Immunol. 1996 May;8(5):773-80. doi: 10.1093/intimm/8.5.773. Int Immunol. 1996. PMID: 8671666 - Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. Yamazaki T, et al. J Immunol. 2002 Nov 15;169(10):5538-45. doi: 10.4049/jimmunol.169.10.5538. J Immunol. 2002. PMID: 12421930 - Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.
Nishimura H, Minato N, Nakano T, Honjo T. Nishimura H, et al. Int Immunol. 1998 Oct;10(10):1563-72. doi: 10.1093/intimm/10.10.1563. Int Immunol. 1998. PMID: 9796923 - Very early (VEA) and very late (VLA) activation antigens have distinct functions in T lymphocyte activation.
Yokoyama WM, Maxfield SR, Shevach EM. Yokoyama WM, et al. Immunol Rev. 1989 Jun;109:153-76. doi: 10.1111/j.1600-065x.1989.tb00024.x. Immunol Rev. 1989. PMID: 2670747 Review. - A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. Okazaki T, et al. Nat Immunol. 2013 Dec;14(12):1212-8. doi: 10.1038/ni.2762. Nat Immunol. 2013. PMID: 24240160 Review.
Cited by
- TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.
Vredevoogd DW, Apriamashvili G, Levy PL, Sinha S, Huinen ZR, Visser NL, de Bruijn B, Boshuizen J, van Hal-van Veen SE, Ligtenberg MA, Bleijerveld OB, Lin CP, Díaz-Gómez J, Sánchez SD, Markovits E, Simon Nieto J, van Vliet A, Krijgsman O, Markel G, Besser MJ, Altelaar M, Ruppin E, Peeper DS. Vredevoogd DW, et al. J Immunother Cancer. 2024 Nov 7;12(11):e010145. doi: 10.1136/jitc-2024-010145. J Immunother Cancer. 2024. PMID: 39510795 Free PMC article. - A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint.
Wang X, Liu T, Li Y, Ding A, Zhang C, Gu Y, Zhao X, Cheng S, Cheng T, Wu S, Duan L, Zhang J, Yin R, Shang M, Gao S. Wang X, et al. Nat Commun. 2024 Oct 23;15(1):9114. doi: 10.1038/s41467-024-53561-2. Nat Commun. 2024. PMID: 39438489 Free PMC article. - Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.
Pavelescu LA, Enache RM, Roşu OA, Profir M, Creţoiu SM, Gaspar BS. Pavelescu LA, et al. Int J Mol Sci. 2024 Sep 6;25(17):9659. doi: 10.3390/ijms25179659. Int J Mol Sci. 2024. PMID: 39273605 Free PMC article. Review. - Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors.
Agostini M, Traldi P, Hamdan M. Agostini M, et al. Int J Mol Sci. 2024 Aug 27;25(17):9276. doi: 10.3390/ijms25179276. Int J Mol Sci. 2024. PMID: 39273224 Free PMC article. Review. - A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer.
Xu X, Yan SL, Yo YT, Chiang P, Tsai CY, Lin LL, Qin A. Xu X, et al. Cancers (Basel). 2024 Sep 1;16(17):3052. doi: 10.3390/cancers16173052. Cancers (Basel). 2024. PMID: 39272910 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous